Colonial Trust Advisors purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,407 shares of the medical instruments supplier’s stock, valued at approximately $450,000. Colonial Trust Advisors owned approximately 0.08% of LeMaitre Vascular as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of LMAT. BNP Paribas Arbitrage SA lifted its position in shares of LeMaitre Vascular by 11,612.5% during the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 3,716 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of LeMaitre Vascular during the second quarter worth about $137,000. Royce & Associates LP acquired a new stake in shares of LeMaitre Vascular during the second quarter worth about $156,000. Royal Bank of Canada lifted its position in shares of LeMaitre Vascular by 856.5% during the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 4,505 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its position in shares of LeMaitre Vascular by 4,751.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 6,355 shares of the medical instruments supplier’s stock worth $198,000 after purchasing an additional 6,224 shares in the last quarter. 66.32% of the stock is currently owned by institutional investors and hedge funds.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) traded down 0.31% during mid-day trading on Friday, reaching $38.49. 13,823 shares of the company traded hands. The company has a market capitalization of $732.16 million, a P/E ratio of 54.99 and a beta of 0.67. The firm’s 50 day moving average price is $36.86 and its 200-day moving average price is $31.11. LeMaitre Vascular, Inc. has a 52-week low of $18.55 and a 52-week high of $39.29.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. The firm had revenue of $25.80 million for the quarter, compared to analyst estimates of $25.42 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. LeMaitre Vascular’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 EPS. Equities analysts predict that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current fiscal year.

LeMaitre Vascular declared that its Board of Directors has initiated a share buyback plan on Thursday, July 27th that allows the company to repurchase $7.50 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 1.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Wednesday, August 23rd were given a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a yield of 0.57%. The ex-dividend date of this dividend was Monday, August 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.88%.

LMAT has been the topic of several research reports. Canaccord Genuity cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 price target on the stock. in a research report on Monday, July 10th. Benchmark Co. cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Monday, July 10th. They noted that the move was a valuation call. BidaskClub cut shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $32.00 target price (up previously from $29.00) on shares of LeMaitre Vascular in a report on Sunday, July 30th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $31.60.

COPYRIGHT VIOLATION NOTICE: “Colonial Trust Advisors Takes $450,000 Position in LeMaitre Vascular, Inc. (LMAT)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/06/colonial-trust-advisors-takes-450000-position-in-lemaitre-vascular-inc-lmat.html.

In related news, CEO George W. Lemaitre sold 11,300 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $32.79, for a total transaction of $370,527.00. Following the transaction, the chief executive officer now directly owns 3,405,508 shares of the company’s stock, valued at approximately $111,666,607.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $37.13, for a total value of $556,950.00. Following the transaction, the chief executive officer now directly owns 3,325,508 shares in the company, valued at $123,476,112.04. The disclosure for this sale can be found here. Insiders have sold a total of 373,121 shares of company stock worth $12,825,992 over the last three months. 23.70% of the stock is currently owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.